In plain terms

The claim being assessed: Once-weekly injectable semaglutide maintenance doses below 0.5 mg cause clinically meaningful sustained weight loss in adults meeting the registered BMI and comorbidity eligibility criteria.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: The evidence reviewed does not show this mechanism causing the outcome. That does not show it has no effect.

Strongest evidence for it: The preregistered primary-subclaim rule returns Γ from SC2. Fifty-nine relevant original reports were examined, but none directly supplies the registered below-0.5 mg weekly, 24-68-week placebo-controlled maintenance experiment. Standard-dose clinical success is preserved as a different proposition. Lower-dose anecdotes, daily dose-ranging and titration do not replace the missing exposure-specific test.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means

Semaglutide works at tested clinical doses; sustained weight-loss efficacy of weekly maintenance strictly below 0.5 mg remains unestablished in this review.

Implications for health and treatment: The preregistered primary-subclaim rule returns Γ from SC2. Fifty-nine relevant original reports were examined, but none directly supplies the registered below-0.5 mg weekly, 24-68-week placebo-controlled maintenance experiment. Standard-dose clinical success is preserved as a different proposition. Lower-dose anecdotes, daily dose-ranging and titration do not replace the missing exposure-specific test. The framework's 'epiphenomenon' role label means a causal role at the exact registered dose is not established by the evidence, not that semaglutide has no effect.

Limits for individual care: 59 primary reports examined. Moderate confidence rests on evidence density and reproducibility, not reading access: no study tests the registered sub-0.5 mg weekly maintenance exposure, the dose-adjacent reports are uncontrolled and response-selected, and muscle and food-noise outcomes conflict or rest on recall. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 61 primary reports (59 in the original audit; 2 added and verified at abstract depth in the 2026-11-02 adversarial review); claims: 67; verified: 67; unverified: 0. Verification is bounded attribution. Access: 3 partial-body and 58 bounded abstract/status examinations. Literature cutoff: 2026-10-13; source examination UTC date: 2026-10-13. No complete-paper audit or blinded calibration claimed.

Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 4 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised. Second adversarial (red-team) pass by Claude Opus 5.5 (Anthropic) on 2026-11-02: 11 corrections applied (A1-A11; see ADVERSARIAL_REVIEW.glp1-microdosing.md); level Γ and confidence Moderate unchanged.

AT A GLANCE

Semaglutide works at tested clinical doses; sustained weight-loss efficacy of weekly maintenance strictly below 0.5 mg remains unestablished in this review.

Deciding experiment: A blinded randomized study in baseline-defined adults meeting the registered BMI criteria, stratified by diabetes, assigns a specified weekly injectable maintenance exposure below 0.5 mg, matched placebo and 2.4 mg with identical behavioral support. Prespecify 52-week weight change and at least 5% responder status, estimands, missingness, adverse events and objective strength/function. A separately randomized de-escalation arm can test maintenance after standard-dose loss without redefining the initial-treatment claim.

Belief versus evidence: The preregistered primary-subclaim rule returns Γ from SC2. Fifty-nine relevant original reports were examined, but none directly supplies the registered below-0.5 mg weekly, 24-68-week placebo-controlled maintenance experiment. Standard-dose clinical success is preserved as a different proposition. Lower-dose anecdotes, daily dose-ranging and titration do not replace the missing exposure-specific test.

Best-supported rival: Multiple appetite and energy-intake pathways support drug response (tournament rank 1; non-nominal); Ε. The 60-week randomized original PMID 42323166 separates a sustained objective intake response from hunger and food-preoccupation contrasts that lose significance after week 20, although food-reward responsiveness still differed at week 40. STEP 3 PMID 33625476 then shows matched behavioral support alone contributes weight loss yet does not explain away the standard-dose drug contrast. Neither is an exact microdose test. The review’s own nominal model — microdose maintenance retains clinical efficacy — is ranked 3 in the tournament and is not the rival.

COMPETING MECHANISTIC MODELS

Rank 3: Microdose maintenance retains clinical efficacy (Γ). The registered low weekly maintenance exposure has sufficient clinical action for sustained weight loss. Short weekly dose-finding and small low/mixed-dose cohorts support plausibility. No matched placebo-controlled 24-68-week exact-exposure original was examined.

Rank 1: Multiple appetite and energy-intake pathways support drug response (Ε). Measured pharmacological exposure lowers intake through multiple central/peripheral pathways without requiring every subjective food-noise score to remain reduced. Randomized appetite/intake studies and STEP clinical trials show real drug benefit; the 60-week trial sustains intake differences after hunger and food-preoccupation contrasts fade, although food-reward responsiveness still differed at week 40. The exact necessary human pathway is not isolated and standard-dose effects do not prove microdose efficacy.

Rank 2: Behavioral energy restriction and clinical support contribute to observed loss (Δ). Calorie goals, counseling and other metabolic treatments produce weight loss alongside or independently of the alleged microdose mechanism. STEP 3 placebo with intensive support loses weight; small PCOS cohorts add metformin; these are plausible cointervention contributions. Placebo/support arms do not explain away randomized standard-dose drug advantages and cannot partition the entire uncontrolled microdose response.

Rank 4: Persistence and response-selected dosing shape apparent low-dose success (Β). Clinicians maintain lower doses partly because of prior success, tolerability and cost, making final dose a consequence of earlier response. FLEX-SEMA explicitly records satisfactory results as the principal maintenance reason; the reduced-frequency case series selects plateau achievers. No randomized dose-assignment test quantifies how much selection explains the apparent effect.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Once-weekly injectable semaglutide maintenance doses below 0.5 mg cause clinically meaningful sustained weight loss in adults with overweight or obesity.

Evaluated wording: Once-weekly injectable semaglutide maintenance doses below 0.5 mg cause clinically meaningful sustained weight loss in adults meeting the registered BMI and comorbidity eligibility criteria. Grammatical clarification only: the original overweight/obesity wording retains the same preregistered BMI eligibility (BMI at least 30, or at least 27 with a weight-related condition), strictly below 0.5 mg weekly maintenance and 24-68 week endpoint. No daily-dose conversion, outcome-defined subgroup or eligibility change is introduced.

The declared clinical causal proposition is represented by SC2. Target engagement, superiority, mechanism, generalization and benefit-harm companions are separately reported and do not substitute for this primary claim.

Selection: position 8 in the registered editorial traffic-priority list; registration timestamp 2026-10-13T15:39:25.266647+00:00. Ranked topics are editorial priorities, not measured worldwide popularity or a preassigned verdict. Registered claim assessed against original sources; no independent blinded calibration is claimed.

Evidence and causal interpretation

Rubric fit: No shipped rubric directly covers obesity-drug efficacy or muscle preservation. Rubric 06 is the nearest metabolic route and is explicitly adapted: a randomized specified drug exposure changing prespecified weight responder/function outcomes is a clinical sufficiency perturbation. Lifespan is not imposed on this treatment claim. Original ladder, caps and verbatim rubric text remain unchanged. Dose/schedule, food-noise necessity and function are independently adjudicated.

The dose schedule decides the main question. The early weekly phase 2 original tested 0.1-0.8 mg without escalation, but followed patients for only 12 weeks and focused on diabetes. The daily obesity dose-ranging trial followed 957 participants for 52 weeks and showed clinically meaningful losses even at low daily doses. Every semaglutide injection in that trial was daily, and the preregistered scope excludes daily-to-weekly conversion. Pharmacologically, however, a sponsor exposure-response model (PMID 37424165) found that systemic exposure, not schedule, explained weight trajectories across the daily 0.05-0.4 mg and weekly 2.4 mg trials; the 0.05 mg daily arm (0.35 mg per week cumulatively) is therefore the closest exposure-matched randomised evidence, and it is the strongest argument a Δ steelman could make.

The clinical success of standard semaglutide remains clear. STEP 1, STEP 2 and other controlled trials demonstrate substantial weight loss at their assigned maintenance exposures; SUSTAIN starts maintenance at 0.5 mg or higher. STEP 4 shows benefit-sensitive continuation versus withdrawal at 2.4 mg in people tolerating run-in. These results support their own clinical settings, not a randomized below-0.5 mg maintenance arm hidden inside escalation.

The closest tailoring reports require careful reading. FLEX-SEMA documents 5.4% remaining on 0.25 mg at three months, but no directly tested exact-dose long-term placebo contrast. Satisfactory prior response drives continued dosing, so a nonsignificant final-dose effect is not noninferiority. The body separates cumulative weight thresholds from nonoverlapping bins, whereas the abstract mislabels bin percentages as cumulative. The PCOS pilot pools 0.25-0.5 mg with metformin and reports a five-month weight assessment; the reduced-frequency series changes timing at an existing dose in plateau achievers. None satisfies the registered maintenance claim. The largest on-exposure dataset points the other way: a federated EHR analysis (PMID 42857675) identified 814 adults with at least three 0.25 mg-only semaglutide prescriptions spanning at least six months, whose mean 12-month weight change was -2.2% (versus -5.5% on sustained 2.5 mg tirzepatide). Observational, uncontrolled for placebo and selected by prescription pattern, it is the closest real-world record of sustained sub-0.5 mg weekly exposure and does not show clinically meaningful (at least 5%) loss.

Food noise deserves a precise construct. INFORM uses the five-item FNQ, but asks current users to remember their pre-treatment state and performs descriptive analysis. Selected Methods and Results confirm 550 survey respondents, 547 complete FNQ responses and many receiving 2.4 mg. The 60-week randomized appetite study instead measures VAS, eating control and food reward. It sustains intake differences while hunger and food-preoccupation contrasts fade after week 20; food-reward responsiveness, the measure closest to food noise, still differed at week 40. This is an informative dissociation, not a direct necessity experiment on the validated FNQ construct.

Muscle outcomes also resist a single slogan. DXA lean loss is not synonymous with weakness. SEMALEAN reports improved grip despite early lean loss at 2.4 mg in an uncontrolled cohort; an older-diabetes retrospective cohort reports decline. STEP UP imaging includes a very small placebo group and preserved chair stands in both pooled semaglutide and placebo groups. HFpEF and osteoarthritis trials provide genuine physical-function benefits under their own clinical conditions. None directly demonstrates that a microdose prevents clinically important muscle dysfunction.

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: primary-subclaim. The preregistered primary-subclaim rule returns Γ from SC2. Fifty-nine relevant original reports were examined, but none directly supplies the registered below-0.5 mg weekly, 24-68-week placebo-controlled maintenance experiment. Standard-dose clinical success is preserved as a different proposition. Lower-dose anecdotes, daily dose-ranging and titration do not replace the missing exposure-specific test. Sensitivities: weakest-link Α; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[1] Randomized 52-week obesity trial found 6.0%-13.8% loss with 0.05-0.4 mg DAILY semaglutide versus 2.3% placebo; gastrointestinal events were dose related. Every active semaglutide dose was administered daily; the trial does not test sub-0.5 mg weekly maintenance or permit arithmetic conversion of exposures.

[2] FLEX-SEMA documented response-selected flexible dosing; 5.4% remained on 0.25 mg at three months, and the original body distinguishes cumulative six-month responders from weight-loss bins. No exact long-term below-0.5 mg placebo contrast; satisfactory prior response drives dose maintenance. Indexed abstract mislabels bin percentages as cumulative thresholds, so original body governs.

[8] Randomized 120-person 60-week 2.4 mg trial sustained lower lunch intake at 20/40/60 weeks while hunger and food-preoccupation contrasts lost significance after week 20; food-reward responsiveness (Power of Food Scale), the measure closest to the food-noise construct, still differed at week 40, and only at week 60 did no subjective contrast remain. Subjective appetite and food-preoccupation dissociation narrows simple mediation, but does not directly remove validated food noise or test microdoses.

[19] INFORM reported lower remembered-to-current FNQ scores in 550 semaglutide users; original Methods/Results confirm 547 complete FNQ responses and descriptive analysis without statistical tests. Recall, panel selection and mixed doses including 2.4 mg do not establish necessary mediation or exact microdose efficacy.

[22] The 415-person randomized 12-week phase 2 study tested weekly 0.1-0.8 mg without escalation and higher escalated doses; glycemic and weight responses were dose dependent. The abstract reports the largest weight effect at 1.6 mg without low-arm estimates; neither duration nor eligibility establishes the registered 24-68-week clinical claim.

[32] STEP 4 randomized 803 participants tolerating 2.4 mg after run-in; continuation caused further loss whereas withdrawal caused regain over 48 weeks. Selection after tolerability and a 2.4 mg regimen do not establish below-0.5 mg microdose maintenance efficacy.

[34] STEP 2 randomized adults with diabetes to 2.4 mg, 1 mg or placebo; 2.4 mg caused 9.6% versus 3.4% loss at 68 weeks. The dose comparison does not contain a below-0.5 mg arm; positive higher-dose effects cannot cross its registered threshold.

[50] A 30-person retrospective series observed maintained weight/body composition after reducing dosing frequency, usually to every other week, at the existing dose. Mixed agents, prior-plateau selection and no control do not test below-0.5 mg once-weekly maintenance against placebo; mass stabilization is not strength preservation.

[51] SEMALEAN followed 115 adults prescribed 2.4 mg; 106 completers showed early lean loss followed by stabilization and improved grip strength. Uncontrolled completion and dose selection cannot prove microdose protection; lean loss and functional decline are distinct outcomes.

[52] A retrospective older-diabetes cohort associated semaglutide with mass and functional decline compared with matched controls over 24 months. Residual confounding, dose choice and comorbidity limit causality; the result does not show every dose causes harm or that microdosing prevents it.

[53] Obese mice lost muscle and fat with semaglutide; adding an ActRII antibody preserved lean mass and improved exercise performance. An added antibody and daily mouse exposure cannot establish human microdose protection; lean-mass correlation does not isolate function causally.

[58] A 20-person PCOS cohort on metformin plus weekly 0.25-0.5 mg observed weight/fat loss and nonsignificant lean-mass change at five months. Pooled doses, metformin and no placebo prevent isolation of below-0.5 mg causality; the reported weight endpoint precedes 24 weeks and BIA is not function.

[60] A federated EHR analysis identified 814 adults with at least three 0.25 mg-only semaglutide prescriptions spanning at least six months; mean 12-month weight change was -2.2% (versus -5.5% on sustained 2.5 mg tirzepatide). Observational, uncontrolled for placebo and selected by prescription pattern, it is the closest real-world record of sustained sub-0.5 mg weekly exposure and does not show clinically meaningful (at least 5%) loss.

Tally: 0 positive qualifying study units across scoped subclaims; 11 screened discriminating contrast units. The eleven discriminating contrasts ([22], [30], [32], [34], [50], [51], [52], [53], [54], [55], [58]) are a different set from the thirteen decisive perturbations printed above. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Zero positive exact-scope SC2 trial units were examined; comparator positives do not count as microdose causal crossings. Short weekly dose-finding is direct-dose-adjacent, not a 24-68-week clinical result. Pooled and secondary reports share parent studies; observed function and muscle mass differ.

No positive field-valid crossing was verified for the registered causal scope in this bounded audit. Pivotal null or negative tests remain informative; their implications depend on comparator quality, target engagement, power and the registered scope.

Cap audit, precedence and Β/Γ/Δ boundary

The positive clinical trials cross within their tested 0.5/1/1.7/2.4 mg or other schedules. Their result cannot cross the strict below-0.5 mg weekly maintenance SC2 by class inference. Animal and biomarker results preserve experimental scope; no universal weak-leg cap is reapplied to a complementary same-scope set.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: All rubric 06 hard rules were reviewed. Clinical weight and objective function are phenotypes. Proxy-only glycemia, imaging without function, single-strain animal inference and unisolated subjective mediation retain their respective limits. No lifespan criterion is imposed on a non-lifespan claim.

SC1 cap: “Biomarker change without functional/phenotypic change caps at Γ.” Weekly dose-finding included 0.1-0.8 mg without escalation over 12 weeks in diabetes, supporting exposure-response plausibility. Its examined abstract does not isolate low-arm appetite effects, and glycemic change alone is not a clinical phenotype crossing. The 1/2.4 mg and oral appetite experiments cannot establish sustained engagement of both registered pathways under the strict microdose maintenance exposure.

SC5 cap: “Mechanistic plausibility plus one-species or in vitro support caps at Γ.” Animal atrophy and co-treatment experiments plus mixed human functional observations support a possible muscle-related pathway. No direct human microdose comparison demonstrates prevention of clinically important strength or function loss. SEMALEAN grip improvement at 2.4 mg is uncontrolled; retrospective older-diabetes decline is confounded; MRI/DXA mass changes and relative lean proportion cannot substitute for function.

Rubric 06 (metabolism-aging) is used here by declared adaptation: its literal lifespan/healthspan field-valid definition and its aging-marker Γ hard rules (ROS, NAD, mitochondrial or senescence measurements alone, single-species evidence, biomarker-only improvement) do not apply to a weight-loss claim and none is triggered, so the applied adaptations listed below for SC1-SC5 are the operative thresholds.

SC1 applied rubric adaptation (distinct from the unchanged literal criterion): Assess actual sub-0.5 mg weekly maintenance exposure and appetite/metabolic readouts; isolated glycemia or pharmacokinetics is a proxy and cannot establish complete functional engagement.

SC2 applied rubric adaptation (distinct from the unchanged literal criterion): Positive causal crossing requires the registered weekly maintenance dose, baseline eligibility, placebo contrast and at least 5% clinical weight loss over 24-68 weeks. Do not convert daily milligrams into weekly equivalence or extract initiation-titration response as long maintenance.

SC3 applied rubric adaptation (distinct from the unchanged literal criterion): Direct matched noninferiority plus benefit-harm outcomes are required. Absence of a significant observational final-dose difference is not evidence of equivalence.

SC4 applied rubric adaptation (distinct from the unchanged literal criterion): Necessity requires a validated food-noise construct and a mediator perturbation or credible dissociation that establishes dependency. Appetite, nausea, craving, energy intake and FNQ are distinct measures.

SC5 applied rubric adaptation (distinct from the unchanged literal criterion): Direct microdose-versus-standard-dose function/strength comparison is required; lean mass, relative lean fraction and heart-failure symptom scores do not establish muscle protection.

Upward threshold ladder

SC1 Δ: Not reached under the applied SC1 adaptation above. Publish arm-specific appetite, intake, exposure and metabolic effects under sustained sub-0.5 mg weekly maintenance, with matched controls and functional outcomes.

SC2 Δ: Not reached under the applied SC2 adaptation above. Randomize baseline-defined eligible adults to specified sub-0.5 mg weekly maintenance, placebo and standard exposure, with prespecified 24-68-week weight outcomes and no responder-defined exclusions.

SC3 Δ: Not reached under the applied SC3 adaptation above. Conduct a prospectively powered direct noninferiority trial versus 2.4 mg using a clinically justified margin and simultaneous adverse-event, discontinuation and functional endpoints.

SC4 Δ: Not reached under the applied SC4 adaptation above. Manipulate or independently dissociate validated food-noise change from drug exposure and intake, while preserving objective weight outcomes and checking mediator-outcome confounding.

SC5 Δ: Not reached under the applied SC5 adaptation above. Measure grip/leg strength, walking/chair stands, muscle quality, nutrition and DXA under randomized exact-dose exposure with age/diabetes strata.

Upper ladder: Therapeutic dose assignment and withdrawal are feasible and represented at higher doses; none supplies the precise registered microdose experiment. Natural/genetic exposure lines do not establish this administered-dose sufficiency or equivalence. The ladder is reachable through the proposed exact-dose controlled study; missing evidence is not an unreachable requirement.

Independence: No assigned subclaim or competing model reaches Ζ. STEP/SUSTAIN repetitions improve clinical confidence without automatically adding independent causal lines. Parent trial reports and pooled analyses share participants; different doses/sponsors alone do not pass the shared-failure test.

Falsification and pitfalls

Necessary subjective food-noise explanation faces an objective-subjective dissociation. In PMID 42323166, intake differences persist at 20/40/60 weeks while hunger and food-preoccupation contrasts lose significance after week 20; food-reward responsiveness (Power of Food Scale), the measure closest to the food-noise construct, still differed at week 40 and only at week 60 did no subjective contrast remain. This is not the same instrument as FNQ and does not directly ablate it. Additional downgrade: False.

Strict microdose equivalence has not passed a direct test. Approved-dose trials and uncontrolled final-dose nulls are not direct microdose noninferiority. No experimental falsification of exact-dose efficacy was examined. Randomised dose-response evidence nevertheless runs against comparability: weight loss rose monotonically from 0.05 to 0.4 mg daily, weekly dose-finding was dose dependent, and 2.0 mg exceeded 1.0 mg weekly (trial-product estimand), while gastrointestinal events were dose related. Lower doses plausibly reduce adverse effects but, on every randomised dose comparison examined, also reduce weight loss. Additional downgrade: False.

Selective generalization. Daily, oral and 0.5/1/2.4 mg effects cannot establish strict weekly microdose maintenance.

Therapeutic effect misread as mechanistic proof. Drug-induced appetite/intake and weight changes do not prove necessary food-noise mediation.

Confirmation by biomarker. Lean mass and its percentage are not strength or clinically important dysfunction.

Scope fitted to outcome. Plateau achievers and satisfactory-response dose selection cannot define baseline microdose efficacy scope.

Replication confused with independence. Secondary STEP/SUSTAIN and pooled reports share parent trials.

Adversarial steelman: above, then below

Δ could be defended because weekly dose-finding includes genuine low-dose arms and lower/mixed-dose cohorts report weight loss. The strongest version would need arm-specific sustained clinical results within the preregistered dose, comparator, baseline eligibility and 24-68-week horizon. Its strongest upward argument is exposure matching: a sponsor exposure-response model (PMID 37424165) found that systemic exposure, not schedule, explained weight trajectories across the daily 0.05-0.4 mg and weekly 2.4 mg trials, making the 0.05 mg daily arm (0.35 mg per week cumulatively; -6.0% versus -2.3% placebo at 52 weeks) the closest exposure-matched randomised evidence. The preregistered scope nevertheless excludes daily-to-weekly conversion.

Β could be defended if the only relevant evidence were uncontrolled weight-loss observations. That undercounts direct short weekly dose-finding and established semaglutide pharmacological plausibility, while properly admitting that these do not establish the long-horizon claim.

Reject Δ because no positive matched exact-scope maintenance experiment was examined; daily and approved-dose evidence cannot repair the missing clinical test. Reject Β because partial direct dose-finding and mechanistic pharmacology support more than co-occurrence. Retain Γ with Moderate appraisal confidence.

Final score, causal direction and M/S/D

The preregistered primary-subclaim rule returns Γ from SC2. Fifty-nine relevant original reports were examined, but none directly supplies the registered below-0.5 mg weekly, 24-68-week placebo-controlled maintenance experiment. Standard-dose clinical success is preserved as a different proposition. Lower-dose anecdotes, daily dose-ranging and titration do not replace the missing exposure-specific test.

For the exact registered microdose mechanism, no demonstrated causal dependency in either direction was examined, so step 2 selects the framework category epiphenomenon. This coarse label records absent exact-scope dependency, not demonstrated biological inertness and not the role of higher-dose semaglutide, whose clinical effects are directly established. The label means a causal role is not established by the evidence, not that the intervention has no effect.

Momentum: Associational only. The exact-dose-adjacent recent originals are FLEX-SEMA, INFORM, the reduced-frequency case series and the small mixed-dose PCOS cohort. Recent randomized clinical work tests standard or higher doses rather than the strict microdose maintenance boundary. No verified named pending exact-dose trial was identified in this bounded search. The largest recent on-exposure record is observational: a 2026 federated EHR cohort (PMID 42857675) of 814 adults on sustained 0.25 mg-only semaglutide observed -2.2% mean 12-month weight change, below the 5% threshold.

Stability: Stable. No verified named pending randomized sub-0.5 mg weekly maintenance result was identified. A future exact-dose placebo trial could raise SC2 or confirm a null, but a generic hypothetical experiment is not a named pending trigger. Named de-escalation trials are registered (REST, NCT07294950, gradual reduction vs cessation, primary completion 2028-09; NCT07783854, tapering vs maintenance non-inferiority, primary completion 2027-12). They test tapering from 1-1.7 mg, not sustained sub-0.5 mg maintenance versus placebo, so Stability remains Stable.

Divergence: Contested. No competent-reader ladder survey or manufactured numeric belief gap is claimed. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

A blinded randomized study in baseline-defined adults meeting the registered BMI criteria, stratified by diabetes, assigns a specified weekly injectable maintenance exposure below 0.5 mg, matched placebo and 2.4 mg with identical behavioral support. Prespecify 52-week weight change and at least 5% responder status, estimands, missingness, adverse events and objective strength/function. A separately randomized de-escalation arm can test maintenance after standard-dose loss without redefining the initial-treatment claim.

Readout: Percent weight change and at least 5% responders at 52 weeks; simultaneous adverse events/discontinuation, validated FNQ, measured intake and objective strength/walking outcomes. Controls: Matched formulation, exposure verification, counseling, follow-up and estimands; retain nonresponders and discontinuers, separate initiation from post-loss de-escalation, and use blinded independent outcome measurement. Supporting: A prespecified positive placebo contrast establishes the first exact-scope clinical crossing; comparator noninferiority with fewer clinically important harms separately supports SC3. Falsifying: No clinically meaningful placebo advantage narrows the efficacy claim without refuting higher-dose semaglutide; inferior weight or function with modest tolerability improvement falsifies promoted equivalence.

KNOWLEDGE GAPS

Direct randomized below-0.5 mg weekly maintenance at 24-68 weeks in the registered baseline BMI population.

Separate low-dose initiation from de-escalation after successful higher-dose loss; retain response/tolerance selection explicitly. Registered de-escalation trials (REST, NCT07294950; NCT07783854) test tapering from 1-1.7 mg, not sustained sub-0.5 mg maintenance versus placebo.

Matched noninferiority and simultaneous benefit-harm comparison against 2.4 mg, rather than final-dose observational nulls.

Prospective validated food-noise measurement and necessary-mediator testing distinct from appetite, cravings, nausea and one-meal intake.

Integrated absolute muscle mass, muscle quality, objective strength/function and nutrition across baseline age/diabetes strata.

Arm-specific low-dose phase 2 data and independent checking of complete bodies/supplements; three selected partial-body checks do not constitute a full-paper audit.

REVIEWER NOTES

59 original reports were examined via original abstracts and linked-status metadata; selected Methods/Results from three original papers were also read and receipted. The 59 are direct-dose-adjacent, comparator, mechanism, functional-boundary and original patient/media studies, not 59 microdosing trials. No exact registered long-term microdose placebo trial was examined. Most bodies and supplements were not audited. Consensus Deep Research supported discovery/aspect reconciliation; its retrieved/included counts are not our examined-primary counts. No independent blinded adjudication or clinical peer review is claimed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

Consensus and original-source reconciliation

Consensus separates the 2.4 mg STEP 1 trial from strict below-0.5 mg maintenance. The examined original confirms 1,961 adults, BMI-defined enrollment, 68 weeks and 14.9% versus 2.4% mean loss. Its 86.4% versus 31.5% at least-5% responder result belongs to 2.4 mg, not the titration step. Original PMID33567185.

Consensus identifies the early weekly phase 2 trial as 12-week boundary evidence. The examined original abstract confirms weekly 0.1-0.8 mg without escalation, higher escalated arms and phase 3 selection of 0.5/1 mg. Low-arm body tables were inaccessible in our public route; we did not promote provider snippets to a full-body audit or a 24-68-week result. Original PMID26358288.

Consensus labels the obesity dose-ranging original as a daily schedule. The examined Methods-containing abstract explicitly says every active dose was once daily. Its 52-week positive weight results therefore do not establish sub-0.5 mg once-weekly maintenance, and no arithmetic dose conversion was used. Original PMID30122305.

Consensus notes this chart review maintained 1 mg or 2 mg. The examined original confirms six-month maintenance in 16 and nine cases respectively, with only 25 completers from 40 patients. Observed losses at these doses and selected completion do not establish the strict microdose or randomized equivalence. Original PMID38826889.

Consensus describes a six-month 0.25-0.5 mg plus-metformin pilot with fat loss and no lean-mass loss. The original reports the weight contrast after five months, combines metformin with pooled semaglutide doses and finds a nonsignificant lean-mass contrast. We retain these distinctions: no isolated below-0.5 mg causal estimate, no registered 24-week weight endpoint and no positive muscle-function protection result. Original PMID41421448.

Consensus characterizes INFORM as retrospective and recall-based. Our selected original Methods and Results independently confirm self-report, no statistical testing, 550 survey participants but 547 complete FNQ responses, and 39% currently using 2.4 mg. The lower recollected-to-current scores do not establish necessary mediation or low-dose efficacy. Original PMID42217114.

Consensus distinguishes SEMALEAN from older-adult retrospective decline. The original SEMALEAN abstract reports 106 completers, initial 3 kg lean-mass loss followed by stabilization and a 4.5 kg grip increase at 12 months during 2.4 mg treatment. Its uncontrolled design supports the distinction between mass and function, not microdose muscle protection. Original PMID41068996.

Consensus identifies the older-adult retrospective cohort as a contrary functional boundary. The original abstract associates exposure with mass and function decline over 24 months but does not establish random allocation or remove nutrition/comorbidity confounding. Neither this finding nor SEMALEAN proves all doses harmful or protective. Original PMID40631351.

FLEX-SEMA was not a cited anchor in the observed Consensus report; our separate original-source retrieval filled this gap. Selected Results show that 5.4% remained on 0.25 mg at three months, while six-month dose maintenance was driven mainly by satisfactory prior results. Body cumulative responder thresholds are 84.4%, 64.6%, 35.4% and 9.4%; the indexed abstract instead mislabels nonoverlapping bin percentages as cumulative. We use the body distinction and do not interpret a final-dose null as noninferiority. Original PMID41725422.

The observed Consensus report explains the need to separate appetite from food noise but does not cite this 60-week original as an anchor. Our selected Methods/Results add the explicit finding: intake and weight differences persist at weeks 40/60 while hunger and food-preoccupation contrasts no longer reach significance. These were VAS/eating-control measures, not a direct intervention on FNQ necessity. Original PMID42323166.

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

Research timeline and gaps: Semaglutide Microdosing and Clinical Outcomes

Selected publication milestones, not an exhaustive history or discovery priority claim.

2016 — Early weekly dose-finding establishes short exposure-response evidence and selects higher doses for phase 3; it is not long microdose maintenance. Original PMID26358288.

2017 — SUSTAIN 1 provides placebo-controlled 0.5/1 mg diabetes results at 30 weeks. Original PMID28110911.

2017 — A small 1 mg weekly crossover study directly measures reduced intake and appetite. Original PMID28266779.

2018 — Daily obesity dose-ranging demonstrates weight effects under a distinct injection schedule. Original PMID30122305.

2020 — SUSTAIN 8 DXA highlights absolute lean loss versus higher lean proportion without function testing. Original PMID31897524.

2021 — STEP 1 establishes 2.4 mg efficacy in BMI-defined non-diabetic adults at 68 weeks. Original PMID33567185.

2021 — STEP 4 demonstrates standard-dose continuation sensitivity after a tolerability run-in. Original PMID33755728.

2022 — Pooled STEP analyses separate gastrointestinal events from most observed weight loss without direct mediator manipulation. Original PMID34514682.

2023 — STEP 5 adds longer-term craving/eating-control measures, with early-only hunger/fullness contrasts. Original PMID36655300.

2023 — SELECT demonstrates hard cardiovascular benefit at the tested standard exposure. Original PMID37952131.

2025 — An older-diabetes retrospective cohort raises a context-specific functional concern requiring causal follow-up. Original PMID40631351.

2026 — SEMALEAN reports improved grip despite early lean loss in an uncontrolled standard-dose cohort. Original PMID41068996.

2026 — FLEX-SEMA documents response-selected flexible dosing; original-body threshold bins require correction of the indexed summary. Original PMID41725422.

2026 — A selected reduced-frequency case series suggests a distinct de-escalation question rather than microdose initiation. Original PMID41732031.

2026 — INFORM introduces semaglutide-specific FNQ recall data but cannot establish necessary mediation. Original PMID42217114.

2026 — A 60-week randomized study separates persistent objective intake/weight effects from waning subjective appetite contrasts. Original PMID42323166.

Research gaps

Direct randomized below-0.5 mg weekly maintenance at 24-68 weeks in the registered baseline BMI population.

Separate low-dose initiation from de-escalation after successful higher-dose loss; retain response/tolerance selection explicitly. Registered de-escalation trials (REST, NCT07294950; NCT07783854) test tapering from 1-1.7 mg, not sustained sub-0.5 mg maintenance versus placebo.

Matched noninferiority and simultaneous benefit-harm comparison against 2.4 mg, rather than final-dose observational nulls.

Prospective validated food-noise measurement and necessary-mediator testing distinct from appetite, cravings, nausea and one-meal intake.

Integrated absolute muscle mass, muscle quality, objective strength/function and nutrition across baseline age/diabetes strata.

Arm-specific low-dose phase 2 data and independent checking of complete bodies/supplements; three selected partial-body checks do not constitute a full-paper audit.

Boundary experiment

A blinded randomized study in baseline-defined adults meeting the registered BMI criteria, stratified by diabetes, assigns a specified weekly injectable maintenance exposure below 0.5 mg, matched placebo and 2.4 mg with identical behavioral support. Prespecify 52-week weight change and at least 5% responder status, estimands, missingness, adverse events and objective strength/function. A separately randomized de-escalation arm can test maintenance after standard-dose loss without redefining the initial-treatment claim.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-14.

Scope of checks: All 59 reference PMIDs re-fetched with the PubMed MCP tool get_article_metadata (title, first author, journal, year, DOI): 59/59 resolve to the stated record; no retraction or expression of concern; the linked correction PMID 41932351 resolves to "Correction to Lancet Diabetes Endocrinol 2025; 13: 935-48", the STEP UP T2D parent. 14 load-bearing claims spot-checked against PubMed abstracts and, for PMIDs 41725422 (FLEX-SEMA), 42217114 (INFORM) and 42323166, against the local full-text/ passages. Scoring logic checked against the archived HSEF v5.3 framework (hard caps first, declared primary-subclaim aggregation, Gamma hard rules, B/Gamma/Delta boundary, independence basis). Safety, purity and dosing statements were audited specifically against what each source reports.

Findings and corrections

Rejected findings (checked, no change)

• Gamma rather than Delta for SC2: no examined source assigns a once-weekly maintenance dose strictly below 0.5 mg over 24-68 weeks against placebo. The daily dose-ranging trial (PMID 30122305) administered every active dose once daily, and SUSTAIN maintenance begins at 0.5 mg; the framework offers no route to Delta without a positive exact-scope perturbation.
• The FLEX-SEMA abstract-versus-body discrepancy the review flags is real: the body reports cumulative six-month thresholds of 84.4%, 64.6%, 35.4% and 9.4%, whereas the indexed abstract presents 23.5%, 34.6%, 30.8% and 11.1% - non-monotone and therefore not cumulative. The review is right to govern by the body. The "5.4% remained at 0.25 mg" figure is in the body verbatim.
• Older-adult sarcopenia cohort (PMID 40631351): the review's description - association of semaglutide with muscle-mass and functional decline over 24 months against matched controls, with confounding and dose choice limiting causality - matches the abstract (220 treated versus 212 controls; reduced ASMI; gait speed reduced in both sexes; dose an independent predictor). Neither overstated nor understated.
• SEMALEAN (PMID 41068996) and the PCOS pilot (PMID 41421448): "improved grip despite early lean loss" and "pools 0.25-0.5 mg with metformin, five-month weight assessment" both match the abstracts.
• STEP 1 figures (1961 randomized, 68 weeks, -14.9% versus -2.4%, 86.4% versus 31.5% at the 5% responder threshold) and SUSTAIN 7, STEP 6, STEP UP T2D and SOUL figures match their records.
• SC3 at Alpha: the "comparable benefit with fewer adverse effects" conjunction has no direct randomized noninferiority or benefit-harm test; Alpha is correct and is not an understatement of harm - the review nowhere asserts that microdosing is safer or safe.
• Momentum "Associational only": no completed study is presented as pending work, and no named pending exact-dose trial was identified. Correct under the lead's momentum policy.
• No dropped collective authors. The declared aggregation rule is primary-subclaim and is applied as written; the Epsilon-level rival is a competing model, not a subclaim, so the scope-matched caution does not apply here.
• Print/e-pub year differences of +/-1 at refs 7, 22, 27, 29, 51, 55 and 58: acceptable under the stated convention.

Residual limitations

• 56 of 59 sources were verified at abstract/status depth; partial-body verification covers the three receipted papers. Per lead policy this bounds what was checked and is not a determinant of the confidence band.
• The review's scope is the dose-response efficacy claim. It does not assess the sourcing of product used for off-label consumer microdosing (compounded or non-prescription supply, labelling accuracy, sterility), and no examined source bears on that; readers should not take the Gamma verdict as any statement about product quality or safety.
• scorecard provenance_header.generated_by reads "Codex; HSEF v5.3". Authorship is recorded here as Sol 6.1 per the mandate; the field was not altered.
• Batch-level files were not edited; propagation strings are listed in the agent report.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-14.

Second adversarial pass (2026-11-02). Claude Opus 5.5 (Anthropic) re-checked all 59 references and 17 load-bearing claims and reported 1 Major, 8 Minor and 2 Editorial findings (A1-A11). All eleven corrections are applied in this edition: the sustained low-dose EHR cohort (reference 60) and the exposure-response model (reference 61) were added after PubMed verification; the food-reward persistence in PMID 42323166, the maintenance (not initiation) scope, the dose-response evidence against equivalence, the epiphenomenon gloss, the rubric-adaptation statement in the cap audit, the registered de-escalation trials and punctuation were corrected. Level Γ and confidence Moderate are unchanged. The full log is ADVERSARIAL_REVIEW.glp1-microdosing.md.

REFERENCES

1. O'Neil PM, Birkenfeld AL, McGowan B et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet (London, England). 2018. PMID 30122305. DOI: 10.1016/S0140-6736(18)31773-2. Access: abstract_metadata. Study: PMID30122305.

2. Pampanelli S, Terzoni S, Pantanetti P et al. Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study. Diabetes, obesity & metabolism. 2026. PMID 41725422. DOI: 10.1111/dom.70538. Access: full_text_partial. Study: PMID41725422.

3. Blundell J, Finlayson G, Axelsen M et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, obesity & metabolism. 2017. PMID 28266779. DOI: 10.1111/dom.12932. Access: abstract_metadata. Study: PMID28266779.

4. Heise T, DeVries JH, Urva S et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes care. 2023. PMID 36857477. DOI: 10.2337/dc22-1710. Access: abstract_metadata. Study: PMID36857477.

5. Friedrichsen M, Breitschaft A, Tadayon S et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, obesity & metabolism. 2021. PMID 33269530. DOI: 10.1111/dom.14280. Access: abstract_metadata. Study: PMID33269530.

6. Gabe MBN, Breitschaft A, Knop FK et al. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Diabetes, obesity & metabolism. 2024. PMID 39082206. DOI: 10.1111/dom.15802. Access: abstract_metadata. Study: PMID39082206.

7. Gibbons C, Blundell J, Tetens Hoff S et al. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes, obesity & metabolism. 2021. PMID 33184979. DOI: 10.1111/dom.14255. Access: abstract_metadata. Study: PMID33184979.

8. Tronieri JS, Allison KC, DeRouen K et al. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. The American journal of clinical nutrition. 2026. PMID 42323166. DOI: 10.1016/j.ajcnut.2026.101403. Access: full_text_partial. Study: NCT05548647.

9. Wilding JPH, Batterham RL, Calanna S et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2021. PMID 33567185. DOI: 10.1056/NEJMoa2032183. Access: abstract_metadata. Study: STEP1-NCT03548935.

10. Kadowaki T, Isendahl J, Khalid U et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The lancet. Diabetes & endocrinology. 2022. PMID 35131037. DOI: 10.1016/S2213-8587(22)00008-0. Access: abstract_metadata. Study: PMID35131037.

11. Hjelmesæth J, Bhat S, Garvey WT et al. Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. Diabetes, obesity & metabolism. 2026. PMID 42764399. DOI: 10.1111/dom.71323. Access: abstract_metadata. Study: STEPUP-NCT05646706.

12. Pratley RE, Aroda VR, Lingvay I et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet. Diabetes & endocrinology. 2018. PMID 29397376. DOI: 10.1016/S2213-8587(18)30024-X. Access: abstract_metadata. Study: PMID29397376.

13. Lingvay I, Bergenheim SJ, Buse JB et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. The lancet. Diabetes & endocrinology. 2025. PMID 40961953. DOI: 10.1016/S2213-8587(25)00225-6. Access: abstract_metadata. Study: PMID40961953.

14. Davies MJ, van der Meer P, Verma S et al. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology. 2025. PMID 39848268. DOI: 10.1016/S2213-8587(24)00304-8. Access: abstract_metadata. Study: STEP-HFpEF-DM-NCT04916470.

15. Mulvagh SL, Inzucchi SE, Marx N et al. Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial. JAMA cardiology. 2026. PMID 41879791. DOI: 10.1001/jamacardio.2026.0245. Access: abstract_metadata. Study: PMID41879791.

16. Tzoulis P, Batavanis M, Baldeweg S. A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss. Cureus. 2024. PMID 38826889. DOI: 10.7759/cureus.59558. Access: abstract_metadata. Study: PMID38826889.

17. de Vere Hunt I, Ramirez-Posada M, Babu CS et al. Patient Experiences With GLP-1 Receptor Agonists. JAMA network open. 2026. PMID 42247231. DOI: 10.1001/jamanetworkopen.2026.16951. Access: abstract_metadata. Study: PMID42247231.

18. Naveed M, Perez C, Ahmad E et al. GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting. Diabetes, obesity & metabolism. 2025. PMID 40259493. DOI: 10.1111/dom.16405. Access: abstract_metadata. Study: PMID40259493.

19. Arnaut T, Duncan S, Faurby M et al. Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey. Advances in therapy. 2026. PMID 42217114. DOI: 10.1007/s12325-026-03636-x. Access: full_text_partial. Study: PMID42217114.

20. Rutigliani G, Mattes RD. The effects of glucagon-like peptide-1 receptor agonists on chemosensory function and ingestive behavior. Physiology & behavior. 2026. PMID 42641845. DOI: 10.1016/j.physbeh.2026.115486. Access: abstract_metadata. Study: PMID42641845.

21. Hayashi D, Kort J, Robles-Martinez IM et al. "And just like that, quiet": a content analysis of TikTok videos on food noise. Nutrition & diabetes. 2026. PMID 42049707. DOI: 10.1038/s41387-026-00423-z. Access: abstract_metadata. Study: PMID42049707.

22. Nauck MA, Petrie JR, Sesti G et al. A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes. Diabetes care. 2016. PMID 26358288. DOI: 10.2337/dc15-0165. Access: abstract_metadata. Study: WEEKLY-SEMA-PHASE2-12W.

23. Sorli C, Harashima SI, Tsoukas GM et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The lancet. Diabetes & endocrinology. 2017. PMID 28110911. DOI: 10.1016/S2213-8587(17)30013-X. Access: abstract_metadata. Study: PMID28110911.

24. Ahrén B, Masmiquel L, Kumar H et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. The lancet. Diabetes & endocrinology. 2017. PMID 28385659. DOI: 10.1016/S2213-8587(17)30092-X. Access: abstract_metadata. Study: PMID28385659.

25. Aroda VR, Bain SC, Cariou B et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The lancet. Diabetes & endocrinology. 2017. PMID 28344112. DOI: 10.1016/S2213-8587(17)30085-2. Access: abstract_metadata. Study: PMID28344112.

26. Rodbard HW, Lingvay I, Reed J et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. The Journal of clinical endocrinology and metabolism. 2018. PMID 29688502. DOI: 10.1210/jc.2018-00070. Access: abstract_metadata. Study: PMID29688502.

27. Ahmann AJ, Capehorn M, Charpentier G et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes care. 2018. PMID 29246950. DOI: 10.2337/dc17-0417. Access: abstract_metadata. Study: PMID29246950.

28. Zinman B, Bhosekar V, Busch R et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. The lancet. Diabetes & endocrinology. 2019. PMID 30833170. DOI: 10.1016/S2213-8587(19)30066-X. Access: abstract_metadata. Study: PMID30833170.

29. Capehorn MS, Catarig AM, Furberg JK et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & metabolism. 2020. PMID 31539622. DOI: 10.1016/j.diabet.2019.101117. Access: abstract_metadata. Study: PMID31539622.

30. Frías JP, Auerbach P, Bajaj HS et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. The lancet. Diabetes & endocrinology. 2021. PMID 34293304. DOI: 10.1016/S2213-8587(21)00174-1. Access: abstract_metadata. Study: PMID34293304.

31. McCrimmon RJ, Catarig AM, Frias JP et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020. PMID 31897524. DOI: 10.1007/s00125-019-05065-8. Access: abstract_metadata. Study: SUSTAIN8-NCT03136484.

32. Rubino D, Abrahamsson N, Davies M et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID 33755728. DOI: 10.1001/jama.2021.3224. Access: abstract_metadata. Study: STEP4-NCT03548987.

33. Wilding JPH, Batterham RL, Davies M et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism. 2022. PMID 35441470. DOI: 10.1111/dom.14725. Access: abstract_metadata. Study: STEP1-NCT03548935.

34. Davies M, Færch L, Jeppesen OK et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London, England). 2021. PMID 33667417. DOI: 10.1016/S0140-6736(21)00213-0. Access: abstract_metadata. Study: STEP2-NCT03552757.

35. Wadden TA, Bailey TS, Billings LK et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021. PMID 33625476. DOI: 10.1001/jama.2021.1831. Access: abstract_metadata. Study: STEP3-NCT03611582.

36. Rubino DM, Greenway FL, Khalid U et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022. PMID 35015037. DOI: 10.1001/jama.2021.23619. Access: abstract_metadata. Study: PMID35015037.

37. Garvey WT, Batterham RL, Bhatta M et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature medicine. 2022. PMID 36216945. DOI: 10.1038/s41591-022-02026-4. Access: abstract_metadata. Study: STEP5-NCT03693430.

38. Wharton S, Batterham RL, Bhatta M et al. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5. Obesity (Silver Spring, Md.). 2023. PMID 36655300. DOI: 10.1002/oby.23673. Access: abstract_metadata. Study: STEP5-NCT03693430.

39. Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine. 2023. PMID 37952131. DOI: 10.1056/NEJMoa2307563. Access: abstract_metadata. Study: SELECT-NCT03574597.

40. Ryan DH, Lingvay I, Deanfield J et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature medicine. 2024. PMID 38740993. DOI: 10.1038/s41591-024-02996-7. Access: abstract_metadata. Study: SELECT-NCT03574597.

41. Kushner RF, Ryan DH, Deanfield J et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring, Md.). 2025. PMID 39948761. DOI: 10.1002/oby.24222. Access: abstract_metadata. Study: SELECT-NCT03574597.

42. Marso SP, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine. 2016. PMID 27633186. DOI: 10.1056/NEJMoa1607141. Access: abstract_metadata. Study: SUSTAIN6-NCT01720446.

43. Perkovic V, Tuttle KR, Rossing P et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England journal of medicine. 2024. PMID 38785209. DOI: 10.1056/NEJMoa2403347. Access: abstract_metadata. Study: FLOW-NCT03819153.

44. Kosiborod MN, Abildstrøm SZ, Borlaug BA et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. The New England journal of medicine. 2023. PMID 37622681. DOI: 10.1056/NEJMoa2306963. Access: abstract_metadata. Study: STEP-HFpEF-NCT04788511.

45. Kosiborod MN, Petrie MC, Borlaug BA et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. The New England journal of medicine. 2024. PMID 38587233. DOI: 10.1056/NEJMoa2313917. Access: abstract_metadata. Study: STEP-HFpEF-DM-NCT04916470.

46. Bliddal H, Bays H, Czernichow S et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England journal of medicine. 2024. PMID 39476339. DOI: 10.1056/NEJMoa2403664. Access: abstract_metadata. Study: PMID39476339.

47. McGowan BM, Bruun JM, Capehorn M et al. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. The lancet. Diabetes & endocrinology. 2024. PMID 39089293. DOI: 10.1016/S2213-8587(24)00182-7. Access: abstract_metadata. Study: PMID39089293.

48. Mu Y, Bao X, Eliaschewitz FG et al. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. The lancet. Diabetes & endocrinology. 2024. PMID 38330988. DOI: 10.1016/S2213-8587(23)00388-1. Access: abstract_metadata. Study: PMID38330988.

49. Lim S, Buranapin S, Bao X et al. Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet. Diabetes & endocrinology. 2025. PMID 40825340. DOI: 10.1016/S2213-8587(25)00164-0. Access: abstract_metadata. Study: PMID40825340.

50. Wong M, Wu A, Garhe PK et al. Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series. Obesity (Silver Spring, Md.). 2026. PMID 41732031. DOI: 10.1002/oby.70137. Access: abstract_metadata. Study: PMID41732031.

51. Alissou M, Demangeat T, Folope V et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes, obesity & metabolism. 2026. PMID 41068996. DOI: 10.1111/dom.70141. Access: abstract_metadata. Study: PMID41068996.

52. Ren Q, Zhi L, Liu H. Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study. Drug design, development and therapy. 2025. PMID 40631351. DOI: 10.2147/DDDT.S531778. Access: abstract_metadata. Study: PMID40631351.

53. Nunn E, Jaiswal N, Gavin M et al. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Molecular metabolism. 2024. PMID 38218536. DOI: 10.1016/j.molmet.2024.101880. Access: abstract_metadata. Study: PMID38218536.

54. Xiang J, Qin L, Zhong J et al. GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway. Diabetes, metabolic syndrome and obesity : targets and therapy. 2023. PMID 37602204. DOI: 10.2147/DMSO.S425642. Access: abstract_metadata. Study: PMID37602204.

55. Wharton S, Calanna S, Davies M et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, obesity & metabolism. 2022. PMID 34514682. DOI: 10.1111/dom.14551. Access: abstract_metadata. Study: STEP1-2-3-4-POOLED.

56. Pandey A, Kitzman DW, Chinnakondepalli KM et al. Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program. JACC. Heart failure. 2025. PMID 40956259. DOI: 10.1016/j.jchf.2025.102610. Access: abstract_metadata. Study: STEP-HFpEF-POOLED.

57. Hendershot CS, Bremmer MP, Paladino MB et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial. JAMA network open. 2026. PMID 42189538. DOI: 10.1001/jamanetworkopen.2026.14898. Access: abstract_metadata. Study: PMID42189538.

58. Bolek T, Turňová P, Janošova S et al. Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study. Clinical nutrition ESPEN. 2026. PMID 41421448. DOI: 10.1016/j.clnesp.2025.102885. Access: abstract_metadata. Study: PMID41421448.

59. Vanek L, Kurnikowski A, Krenn S et al. Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study. Diabetes, obesity & metabolism. 2024. PMID 39375862. DOI: 10.1111/dom.15967. Access: abstract_metadata. Study: PMID39375862.

60. Murugadoss K, Venkatakrishnan AJ, Soundararajan V. Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide. Biology methods & protocols. 2026. PMID 42857675. DOI: 10.1093/biomethods/bpag048. Access: abstract_metadata. Study: PMID42857675.

61. Strathe A, Horn DB, Larsen MS et al. A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity. Diabetes, obesity & metabolism. 2023. PMID 37424165. DOI: 10.1111/dom.15211. Access: abstract_metadata. Study: PMID37424165.

Source-specific evidence cards

[1] Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.

Shows: Randomized 52-week obesity trial found 6.0%-13.8% loss with 0.05-0.4 mg DAILY semaglutide versus 2.3% placebo; gastrointestinal events were dose related.

Does not show: Every active semaglutide dose was administered daily; the trial does not test sub-0.5 mg weekly maintenance or permit arithmetic conversion of exposures.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[2] Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.

Shows: FLEX-SEMA documented response-selected flexible dosing; 5.4% remained on 0.25 mg at three months, and the original body distinguishes cumulative six-month responders from weight-loss bins. The same source reports adverse events in 56.8% of patients at three months and 32.6% at six months, early discontinuation rising from 6.3% to 10.5%, and dose maintenance attributed to satisfactory results (40%), cost (30%) and adverse events (27.5%).

Does not show: No exact long-term below-0.5 mg placebo contrast; satisfactory prior response drives dose maintenance. Indexed abstract mislabels bin percentages as cumulative thresholds, so original body governs.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:MATERIALS AND METHODS:paragraph0, 1:MATERIALS AND METHODS:paragraph1, 1:MATERIALS AND METHODS:paragraph7, 1:MATERIALS AND METHODS:paragraph8, 2:RESULTS:paragraph1, 2:RESULTS:paragraph3, 2:RESULTS:paragraph14, 2:RESULTS:paragraph15, 2:RESULTS:paragraph16, 2:RESULTS:paragraph19. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[3] Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.

Shows: Thirty-person randomized crossover at 12 weeks and 1 mg weekly reduced daily ad-libitum intake 24% and body weight 5 kg with altered appetite and food cravings.

Does not show: Dose escalated to 1 mg; early 0.25 mg titration is not isolated; eating-control measures are not necessary food-noise mediator perturbations.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[4] Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.

Shows: Secondary randomized tirzepatide 15 mg versus semaglutide 1 mg versus placebo analysis found greater weight/fat loss with tirzepatide despite similar measured appetite and meal-intake changes between drugs.

Does not show: One meal/intake instrument does not isolate full energy balance or validated food-noise necessity; no microdose or muscle-function prevention tested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4, SC5.

[5] The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.

Shows: Seventy-two-person randomized 20-week trial of 2.4 mg weekly reduced intake 35%, weight 9.9% and hunger/cravings versus placebo; no late gastric-emptying delay by indirect test.

Does not show: No sub-0.5 mg maintenance or specific food-noise mediator manipulation; paracetamol absorption is an indirect gastric-emptying instrument.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[6] Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial.

Shows: Randomized 61-person 20-week oral 50 mg trial reduced energy intake and appetite with 9.8% weight loss versus 1.5% placebo.

Does not show: Oral daily bioavailability and exposure differ from weekly injectable microdoses; appetite changes do not prove necessary food-noise mediation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[7] Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.

Shows: Small crossover oral 14 mg daily trial in T2D reduced evaluated daily intake 38.9% and weight 2.7 kg versus 0.1 kg placebo with mixed meal-context appetite responses.

Does not show: Thirteen evaluable subjects and oral formulation cannot establish weekly microdose maintenance; no mediator ablation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[8] Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial.

Shows: Randomized 120-person 60-week 2.4 mg trial sustained lower lunch intake at 20/40/60 weeks while hunger and food-preoccupation contrasts lost significance after week 20; food-reward responsiveness (Power of Food Scale), the measure closest to the food-noise construct, still differed at week 40, and only at week 60 did no subjective contrast remain.

Does not show: Subjective appetite and food-preoccupation dissociation narrows simple mediation, but does not directly remove validated food noise or test microdoses.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph1, 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph8, 1:Methods:paragraph12, 2:Results:paragraph8, 2:Results:paragraph10, 2:Results:paragraph19, 2:Results:paragraph21, 2:Results:paragraph22. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC4.

[9] Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Shows: STEP 1 randomized 1961 eligible non-diabetic adults to 2.4 mg weekly; 68-week mean weight loss 14.9% versus 2.4% placebo and 5% responders 86.4% versus 31.5%.

Does not show: Drug efficacy at 2.4 mg with lifestyle support does not cross sub-0.5 mg maintenance threshold; participant-reported function does not isolate muscle preservation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC5.

[10] Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.

Shows: STEP 6 compared 2.4/1.7 mg weekly with placebo in 401 East Asian adults; 68-week mean losses 13.2/9.6% versus 2.1%, mapping a dose/context boundary.

Does not show: Both doses greatly exceed microdose definition; visceral-fat imaging does not establish muscle function or microdose equivalence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC5.

[11] Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP.

Shows: STEP UP MRI subset pooled 49 semaglutide 7.2/2.4 mg versus 6 placebo showed less fat infiltration and preserved sit-to-stand repetitions despite volume loss.

Does not show: Tiny imbalanced subset with same 13-to-15 chair stands in both groups gives no positive microdose muscle-function prevention result; 72 weeks lies beyond registered weight horizon.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[12] Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.

Shows: SUSTAIN 7 randomized 1201 T2D patients; 0.5/1 mg weekly reduced weight 4.6/6.5 kg versus 2.3/3 kg dulaglutide at 40 weeks.

Does not show: 0.5 mg is explicitly excluded by strict below 0.5 mg registration; no placebo or matched 2.4 mg microdose-equivalence comparison.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[13] Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.

Shows: STEP UP T2D randomized 512 adults to 7.2/2.4 mg or placebo; 7.2 mg produced 13.2% versus 3.9% loss with dose-related dysaesthesia imbalance.

Does not show: No sub-0.5 mg maintenance; 72-week horizon and parent-linked correction 41932351 must remain explicit; no muscle prevention outcome here.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID41932351. Subclaims: SC2, SC3, SC5.

[14] Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.

Shows: STEP-HFpEF DM secondary analysis found 2.4 mg weekly improved symptom/physical-limitations scores and weight across baseline HbA1c strata in 616 adults.

Does not show: Heart-failure function is not dose-specific muscle-strength preservation; subgroup report shares parent trial and does not test microdose maintenance.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

[15] Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial.

Shows: SOUL posthoc secondary analysis of 9650 randomized high-risk T2D adults found oral 14 mg exposure improved multiple risk factors and weight beyond placebo over 156 weeks.

Does not show: Oral exposure, long horizon and surrogate contrasts do not establish weekly microdose benefits or comparable clinical benefit-harm profile.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[16] A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss.

Shows: Forty-person retrospective obesity series found observed loss at 3 months and in 25 six-month completers; maintenance was 1 mg in 16 and 2 mg in 9.

Does not show: Lower-than-obesity-dose is not below 0.5 mg; uncontrolled attrition/completion and dose selection preclude microdose causality or noninferiority.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[17] Patient Experiences With GLP-1 Receptor Agonists.

Shows: Qualitative interviews with 30 current/former GLP1 users describe reduced food noise, adverse effects, cost barriers and lifestyle facilitation.

Does not show: Recruited testimonials without randomized mediator contrast cannot demonstrate necessary food-noise mechanism or exact-dose efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[18] GLP-1 medication and weight loss: Barriers and motivators among 1659 participants managed in a virtual setting.

Shows: Surveys/video diaries among 1659 virtual-care participants describe reduced food thoughts and satiety alongside cost, stigma and side-effect discontinuation.

Does not show: Mixed drugs and self-report with selection do not isolate semaglutide microdose effects or causal necessity of food-noise reduction.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[19] Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey.

Shows: INFORM reported lower remembered-to-current FNQ scores in 550 semaglutide users; original Methods/Results confirm 547 complete FNQ responses and descriptive analysis without statistical tests.

Does not show: Recall, panel selection and mixed doses including 2.4 mg do not establish necessary mediation or exact microdose efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 2:Methods:paragraph1, 2:Methods:paragraph3, 2:Methods:paragraph4, 2:Methods:paragraph5, 2:Methods:paragraph11, 2:Methods:paragraph13, 3:Results:paragraph0, 3:Results:paragraph1, 3:Results:paragraph4. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[20] The effects of glucagon-like peptide-1 receptor agonists on chemosensory function and ingestive behavior.

Shows: Cross-sectional 79-person GLP1RA study associated 6-month use with lower FNQ, food reward and intake; protein intake did not differ significantly.

Does not show: Separate exposure groups and mixedagents/doses do not establish longitudinal mediation or muscle-strength preservation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4, SC5.

[21] "And just like that, quiet": a content analysis of TikTok videos on food noise.

Shows: Original 99-video TikTok analysis found food-noise content dominated by patient testimony and usually positive medication portrayals.

Does not show: Engagement and reported experience describe promotion, not causal clinical efficacy; no field-wide HSEF belief survey or microdose comparison.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[22] A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.

Shows: The 415-person randomized 12-week phase 2 study tested weekly 0.1-0.8 mg without escalation and higher escalated doses; glycemic and weight responses were dose dependent.

Does not show: The abstract reports the largest weight effect at 1.6 mg without low-arm estimates; neither duration nor eligibility establishes the registered 24-68-week clinical claim.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

[23] Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.

Shows: SUSTAIN 1 found 3.73/4.53 kg weight loss with weekly 0.5/1 mg versus 0.98 kg with placebo at 30 weeks.

Does not show: Both doses lie outside the strict below-0.5 mg registration; the trial does not isolate microdose efficacy in the specified obesity population.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[24] Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

Shows: SUSTAIN 2 found 4.3/6.1 kg loss with weekly 0.5/1 mg versus 1.9 kg with sitagliptin at 56 weeks, with more adverse-event discontinuation.

Does not show: Excluded doses and an active comparator cannot establish microdose noninferiority to 2.4 mg or fewer harms.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[25] Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.

Shows: SUSTAIN 4 found weight loss with weekly 0.5/1 mg versus weight gain with glargine at 30 weeks, with fewer hypoglycemic events.

Does not show: The open-label comparison, background drugs and excluded doses provide no direct microdose maintenance evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[26] Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.

Shows: SUSTAIN 5 found 3.7/6.4 kg loss with weekly 0.5/1 mg versus 1.4 kg with placebo in basal-insulin-treated diabetes.

Does not show: No below-0.5 mg maintenance arm was randomized; diabetes and insulin context must remain explicit.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[27] Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

Shows: SUSTAIN 3 found 5.6 kg loss with weekly 1 mg versus 1.9 kg with extended-release exenatide at 56 weeks, with more gastrointestinal events.

Does not show: Open-label approved-dose comparison does not establish microdose efficacy or equivalence to 2.4 mg.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[28] Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.

Shows: SUSTAIN 9 found 1 mg weekly added to SGLT2 therapy reduced weight beyond placebo; 0.25 mg was used only during four-week titration.

Does not show: Titration cannot be credited as maintenance; three parent-linked errata are recorded without inventing their unexamined contents.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID30872122; ErratumIn: PMID31272930; ErratumIn: PMID31621596. Subclaims: SC2, SC3.

[29] Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).

Shows: SUSTAIN 10 found 5.8 kg loss with weekly 1 mg versus 1.9 kg with daily liraglutide at 30 weeks, with more gastrointestinal discontinuation.

Does not show: No microdose arm; malformed inequality glyphs in the indexed abstract are not reproduced as precise threshold claims.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[30] Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.

Shows: SUSTAIN FORTE found a 2-versus-1 mg weight advantage significant under the trial-product estimand but not under treatment policy at 40 weeks.

Does not show: Both doses are excluded; estimand-dependent superiority cannot establish microdose noninferiority or lower harm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[31] Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.

Shows: SUSTAIN 8 DXA results showed lean mass decreased despite increased lean proportion, with nonsignificant semaglutide-versus-canagliflozin differences.

Does not show: Only 114 of 178 had end-treatment data; no placebo, strength or function measurement establishes muscle dysfunction or protection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[32] Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Shows: STEP 4 randomized 803 participants tolerating 2.4 mg after run-in; continuation caused further loss whereas withdrawal caused regain over 48 weeks.

Does not show: Selection after tolerability and a 2.4 mg regimen do not establish below-0.5 mg microdose maintenance efficacy.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC5.

[33] Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.

Shows: The exploratory STEP 1 extension found regain of roughly two-thirds of prior weight loss after drug and lifestyle support stopped.

Does not show: Selected completers, shared parent data and simultaneous withdrawal of lifestyle support limit independent inference; no microdose arm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[34] Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Shows: STEP 2 randomized adults with diabetes to 2.4 mg, 1 mg or placebo; 2.4 mg caused 9.6% versus 3.4% loss at 68 weeks.

Does not show: The dose comparison does not contain a below-0.5 mg arm; positive higher-dose effects cannot cross its registered threshold.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[35] Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.

Shows: STEP 3 found 16.0% versus 5.7% weight loss with 2.4 mg versus placebo alongside matched intensive behavioral support.

Does not show: A matched diet and counseling bundle does not isolate titration-dose maintenance or justify a microdose claim.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[36] Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Shows: STEP 8 found 15.8% loss with weekly 2.4 mg versus 6.4% with daily liraglutide at 68 weeks.

Does not show: Active comparisons were open-label with different titration/tolerability options; no microdose noninferiority was tested.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[37] Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.

Shows: STEP 5 found sustained 15.2% versus 2.6% loss with weekly 2.4 mg versus placebo at 104 weeks.

Does not show: The high dose and longer horizon provide genuine comparator efficacy but not the registered microdose result.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[38] Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.

Shows: The STEP 5 eating-control subset showed sustained improvements in some craving domains correlated with weight loss; hunger/fullness effects were early.

Does not show: Subset selection, multiplicity and correlation cannot show necessary mediation by a validated food-noise construct; this shares STEP 5 participants.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC4.

[39] Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

Shows: SELECT found fewer major cardiovascular events with 2.4 mg than placebo in 17,604 adults with cardiovascular disease and no diabetes, with more discontinuation.

Does not show: Hard clinical benefit at the tested dose does not establish comparable microdose benefit-harm or dose-specific noninferiority.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[40] Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.

Shows: SELECT anthropometric analysis found sustained 10.2% versus 1.5% weight loss at 208 weeks across baseline BMI strata.

Does not show: Shared SELECT participants and flexible dose histories do not supply randomized below-0.5 mg maintenance evidence.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[41] Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial.

Shows: SELECT safety analysis found fewer serious events but more gastrointestinal discontinuation and gallbladder disorders with semaglutide.

Does not show: Endpoint-specific benefit-harm and shared trial data cannot demonstrate a microdose safety advantage.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[42] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Shows: SUSTAIN 6 found fewer pooled major cardiovascular events but more retinopathy complications with weekly 0.5/1 mg in high-risk diabetes.

Does not show: Both doses are excluded; pooled dose effects and noninferiority design cannot establish microdose hard outcomes or a uniformly safer profile.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[43] Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

Shows: FLOW found fewer major kidney-composite events with weekly 1 mg versus placebo over 3.4 years in diabetes and kidney disease.

Does not show: The dose, kidney-defined population and long horizon are specific; genuine benefit cannot be inherited by microdose claims.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[44] Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.

Shows: STEP-HFpEF found 2.4 mg improved six-minute walking and symptom/physical-limitations scores beyond placebo in obesity-related heart failure.

Does not show: Exercise improvement is real but does not isolate muscle preservation or test low-dose dysfunction prevention.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[45] Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.

Shows: STEP-HFpEF DM found 2.4 mg improved walking and symptom/physical-limitations scores in obesity-related heart failure and diabetes.

Does not show: Cardiorespiratory function is not isolated muscle strength; later analyses share this parent trial and contain no microdose arm.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[46] Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.

Shows: STEP 9 found 2.4 mg improved weight, knee pain and reported physical function more than placebo at 68 weeks.

Does not show: Osteoarthritis symptom relief is not proof of microdose muscle preservation or prevention of sarcopenia.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

[47] Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.

Shows: STEP 10 found 13.9% versus 2.7% weight loss with 2.4 mg versus placebo at 52 weeks in obesity and prediabetes.

Does not show: Clinical efficacy belongs to the tested standard-dose context; normoglycemia is not proof of comparable microdose hard outcomes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[48] Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.

Shows: STEP 7 found 12.1% versus 3.6% loss with 2.4 mg versus placebo in predominantly East Asian adults at 44 weeks.

Does not show: Population replication of one pharmacological modality does not create direct microdose evidence or an independent causal line.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[49] Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial.

Shows: STEP 11 found 16.0% versus 3.1% loss with 2.4 mg versus placebo at 44 weeks in Asian adults selected by BMI at least 25.

Does not show: Some enrollment lies outside the fixed obesity eligibility; whole-cohort effects cannot supply an exact-scope microdose estimate.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[50] Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series.

Shows: A 30-person retrospective series observed maintained weight/body composition after reducing dosing frequency, usually to every other week, at the existing dose.

Does not show: Mixed agents, prior-plateau selection and no control do not test below-0.5 mg once-weekly maintenance against placebo; mass stabilization is not strength preservation.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3, SC5.

[51] Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.

Shows: SEMALEAN followed 115 adults prescribed 2.4 mg; 106 completers showed early lean loss followed by stabilization and improved grip strength.

Does not show: Uncontrolled completion and dose selection cannot prove microdose protection; lean loss and functional decline are distinct outcomes.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[52] Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study.

Shows: A retrospective older-diabetes cohort associated semaglutide with mass and functional decline compared with matched controls over 24 months.

Does not show: Residual confounding, dose choice and comorbidity limit causality; the result does not show every dose causes harm or that microdosing prevents it.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[53] Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.

Shows: Obese mice lost muscle and fat with semaglutide; adding an ActRII antibody preserved lean mass and improved exercise performance.

Does not show: An added antibody and daily mouse exposure cannot establish human microdose protection; lean-mass correlation does not isolate function causally.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[54] GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway.

Shows: Obese mice and myotubes showed less atrophy with liraglutide/semaglutide, with effects attenuated after SIRT1 inhibition.

Does not show: Single-strain and cell-inhibitor results have system and specificity limits and do not establish weekly human microdose protection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[55] Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.

Shows: Pooled STEP analyses found similar weight loss with and without gastrointestinal events; statistical mediation estimated little nausea-related contribution.

Does not show: Postrandomization grouping is not mediator manipulation; nausea is not food noise, and pooled reports do not create microdose noninferiority.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[56] Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.

Shows: Pooled STEP-HFpEF analyses found lower multidomain frailty burden with 2.4 mg and greater symptom benefit in the most frail baseline group.

Does not show: A frailty index is not isolated muscle strength; the two shared parent trials cannot establish microdose protection.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC5.

[57] Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.

Shows: A 24-person nine-week smoking trial found lower weight and nicotine craving despite null primary laboratory smoking interactions.

Does not show: 0.25 mg was only four-week titration before escalation; short exposure and nicotine craving cannot test food-noise necessity or weight maintenance.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC4.

[58] Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective study.

Shows: A 20-person PCOS cohort on metformin plus weekly 0.25-0.5 mg observed weight/fat loss and nonsignificant lean-mass change at five months.

Does not show: Pooled doses, metformin and no placebo prevent isolation of below-0.5 mg causality; the reported weight endpoint precedes 24 weeks and BIA is not function.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC5.

[59] Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study.

Shows: A 13-person dialysis cohort observed 4.6 kg mean loss over 12 weeks with escalation from 0.25 to 0.5 to 1 mg.

Does not show: Uncontrolled special-population exposure, short duration and mixed escalation do not test microdose maintenance.

Access/status: Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[60] Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide.

Shows: A federated EHR analysis identified 814 adults with at least three 0.25 mg-only semaglutide prescriptions spanning at least six months; mean 12-month weight change was -2.2% (versus -5.5% on sustained 2.5 mg tirzepatide).

Does not show: Observational, uncontrolled for placebo and selected by prescription pattern, it is the closest real-world record of sustained sub-0.5 mg weekly exposure and does not show clinically meaningful (at least 5%) loss.

Access/status: Original primary abstract and linked-status metadata examined via PubMed on 2026-11-02 during the second adversarial review; no complete-abstract, complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[61] A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.

Shows: A population pharmacokinetic and exposure-response model built on the daily 0.05-0.4 mg dose-ranging trial and two weekly 2.4 mg phase 3 trials found that systemic exposure over time consistently explained weight-loss trajectories across trials and dosing regimens.

Does not show: A sponsor model of exposure, not a randomized test of sustained sub-0.5 mg weekly maintenance; it makes the 0.05 mg daily arm the closest exposure-matched randomized evidence but does not override the preregistered exclusion of daily-to-weekly conversion.

Access/status: Original primary abstract and linked-status metadata examined via PubMed on 2026-11-02 during the second adversarial review; no complete-abstract, complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• ADVERSARIAL_REVIEW.glp1-microdosing.md
• CONSENSUS_CROSSCHECK.html
• CONSENSUS_CROSSCHECK.md
• RESEARCH_TIMELINE.html
• RESEARCH_TIMELINE.md
• SHA256.txt
• adversarial-findings.glp1-microdosing.json
• codex-correction-provenance.json
• consensus-validation.json
• edition-approval-audit.json
• glp1-microdosing.review.md
• glp1-microdosing.scorecard.json
• reader-summary.json
• research-timeline.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt
• video-insert.md
• web-page.md

Sources: 61 · load-bearing claims: 67 · verified: 67 · unverified: 0 · contradicted: 0 · schema 5.3